Osimertinib belongs to the 3rd generation EGFR-TKIs and is the only drug currently available for the treatment of NSCLC with EGFR-T790M mutation-positive and resistance to 1st generation EGFR-TKIs [8]. Here, EGFR is linked to non-small cell lung carcinoma.